Coexisting Moyamoya Syndrome and Type 1 Diabetes Mellitus: A Case Report and Review of the Literature

Abstract
Moyamoya disease (MMD) is an incompletely understood malady that affects many age groups, primarily in a bimodal age distribution. We present a patient with the association of type 1 diabetes mellitus (type 1 DM) and MMD followed by a review of the existing literature. We found five papers that describe this association, in the form of one case report, one case series, and three retrospective reviews. Despite a poor understanding of the underlying pathophysiology, a clear association between autoimmune conditions and MMD appears to exist. Clinicians who manage such patients ought to be vigilant and have a high index of suspicion when young patients with type 1 DM present with new onset of neurological symptoms.

Keywords: Chorea, external carotid–internal carotid bypass, hemiballismus, moyamoya disease, type 1 diabetes mellitus

Introduction
Moyamoya disease (MMD) is a progressive idiopathic intracranial occlusive disease that primarily affects bilateral terminal internal carotid arteries (TICAs), proximal middle cerebral arteries (MCA), and anterior cerebral arteries. Affected patients present with symptoms related to regional cerebral ischemia in the form of transient ischemic attacks, stroke, and seizures. Some patients present with cognitive decline, personality changes, and movement disorders. Headache is another important clinical feature that occurs due to the dilatation of meningeal collaterals. Intracranial hemorrhage usually occurs due to neovascularization or rupture of flow-related aneurysms, especially in the posterior circulation.[1] Although MMD occurs at all ages, it usually follows a bimodal distribution, affecting children aged <10 years or adults in their 40s. Females and persons of Asian ancestry are affected more commonly.[2-5]

The exact pathogenesis of MMD remains poorly understood. Familial MMD shows an autosomal-dominant inheritance pattern with incomplete penetrance. Chromosome 17q25 has been implicated in the development of MMD.[6] Recent reports have described associations with various autoimmune disorders.[7-10] Diffuse hyperplasia of the smooth muscle cells occurs in the affected arteries, without any atherosclerotic or inflammatory changes.[11] We present the clinical, imaging, cerebral hemodynamic features and management approach in a patient with type 1 diabetes mellitus (DM), alopecia areata, and MMD along with a review of the available literature.

Case Report
A 21-year-old Malay woman presented with hemiballismus involving the left upper and lower limb for 2 days. Although the movements had reduced in intensity, they occurred even during sleep. She was diagnosed with type 1 DM at the age of 9 years when she presented with diabetic ketoacidosis. Her acute episode was treated, and he was started on insulin for long-term control. She was subsequently diagnosed with alopecia areata, bronchial asthma, and vitiligo.

Blood sugar on hospital arrival was 28 mmols/L (normal range 4.0–7.8 mmols/L). Magnetic resonance (MR) imaging of the brain showed abnormal signals in the right basal ganglia [Figure 1a] while computerized tomographic angiography demonstrated...
severe steno-occlusive disease of both TICAs [Figure 1b] with numerous collaterals in Moyamoya pattern. Blood tests for vasculitic disorders (including erythrocyte sedimentation rate, systemic lupus erythematosus panel, rheumatoid factor, and antinuclear antigen) were unremarkable.

Transcranial Doppler (TCD) ultrasonography revealed multiple waveform patterns in the MCA regions due to various collaterals, consistent with Moyamoya pattern. Her vasodilatory reserve in both MCAs, evaluated during the hypercapnic challenge, showed an exhausted response with paradoxical reduction of the flow velocities (Reversed Robin Hood syndrome).[12] Mean flow velocity (MFV) in the right MCA reduced from 32 cm/s to 23 cm/s during 30 s of voluntary breath holding while the MFV of the left MCA reduced from 36 cm/s to 32 cm/s during the same period [Figure 2].

Treatment with intravenous insulin and oral clonazepam gradually reduced the hemiballistic movements. Clonazepam was gradually tapered during the following 2 weeks. She underwent an uneventful right superficial temporal artery-to-MCA bypass (STA-MCA) surgery after 2 weeks. However, she developed mild left hemiplegia on the 5th postoperative day. Although MR imaging of the brain showed an acute infarction in the right MCA territory, the STA-MCA bypass was patent [Figure 3]. With rehabilitative physiotherapy, she recovered rapidly and became independent for all activities of daily living during the next 2 weeks. TCD performed 4 months after the surgery revealed normal vasodilatory reserve in the right MCA (breath holding index 0.8; normal >0.69). However, the left MCA still showed an impaired response (breath holding index 0.13). Left EC-IC indirect bypass surgery was performed on the left side 6 months later, which improved the vasodilatory reserve on the left side also. She has remained well during the follow-up during the past year.

**Discussion**

Our patient presented with hemiballismus. We believe that the right basal ganglia lesion occurred due to a combination of hyperglycemia and MMD-induced ischemia.[13]

An extensive literature search in “PubMed,” “Google Scholar,” and “Scopus” using the terms such as “Type 1 Diabetes Mellitus,” “Moyamoya disease,” and “Moyamoya disease and autoimmune diseases” revealed 5 publications between 2012 and 2016 that included 1 case series, 1 case report, and 3 retrospective reviews of individual patient data.[14-18]

The case report from Japan in 2015 described a young woman who developed stroke symptoms after 26 years with type 1 DM. She was investigated and found to have a concurrent MMD. Interestingly, Moyamoya cases related to autoimmune conditions in Japan are surprisingly rare given the relatively higher incidence of MMD in Japan.[14]

Hughes et al. described 4 women with type 1 DM and MMD, 3 in their 20s and one in 36 years of age at the time of diagnosis.[15] Two of them also had Grave’s
disease and one suffered from concomitant systemic lupus erythematosus (SLE). Bilateral TICAs were affected in 3 of them. All patients presented with cerebral ischemic symptoms.

In a retrospective analysis of Western Chinese population, Chao et al. described 142 patients with MMD, of which 18 (12.7%) suffered from some kind of autoimmune disorder. While 7% patients suffered from type 1 DM, gestational diabetes occurred in 8.3%, showing considerably higher prevalence of autoimmune conditions among the normal Chinese population (1.2% and 0.34%, respectively). Similar higher prevalence of type 1 DM was reported among the MMD patients in the Mayo Clinic database from 1980 to 2011 (8.4% compared to 0.4% among the general US population). A significant relationship was also noted between MMD and thyroid disorders in that database (Grave’s disease in 2.1% and thyroiditis in 14.9% vs. 0.43% and 7.6%, respectively, in the General US population). On the contrary, a recent US study of predominantly Caucasian patients from Kentucky region explored the relationship between MMD and autoimmune disorders in 31 patients. Although such disorders were noted in 26% patients, no significant association was noted with DM. Even the severity of DM and Suzuki grade of MMD.

Higher prevalence of autoimmune disorders suggests that they may contribute toward the development of MMD. Although type 1 DM and Grave’s disease seem to have the strongest association, other conditions such as SLE, Polyarteritis nodosa, Sneddon syndrome and Antiphospholipid syndrome, Anti-Ro and Anti-La antibodies have also been reported to coexist with MMD in relatively higher prevalence. Although cerebral vasculitis occurs in some of the autoimmune disorders, it is usually transient and often responds to corticosteroids and other immune modulators. However, whether the commonly used immunomodulatory therapy for various autoimmune disorders provide any benefit to MMD remains unknown. Perhaps, a large multinational longitudinal registry of patients with MMD with autoimmune disorders may provide answers to this important question and open some treatment avenues for patients with MMD.

Conclusion

The etiopathogenesis of MMD remains poorly understood. The limited available data suggest that patients with MMD should also be considered for investigation for common autoimmune conditions, especially DM and Grave’s disease.

Acknowledgments

We would like to thank all medical personnel involved in the patient’s care and rehabilitation.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

1. Scott RM, Smith ER. Moyamoya disease and Moyamoya syndrome. N Engl J Med 2009;360:1226-37.
2. Baba T, Houkin K, Kuroda S. Novel epidemiological features of Moyamoya disease. J Neurol Neurosurg Psychiatry 2008;79:900-4.
3. Wakai K, Tamakoshi A, Ikezaki K, Fukui M, Kawamura T, Aoki R, et al. Epidemiological features of Moyamoya disease in Japan: Findings from a nationwide survey. Clin Neurol Neurosurg 1997;99 Suppl 2:S1-5.
4. Han DH, Nam DH, Oh CW. Moyamoya disease in adults: Characteristics of clinical presentation and outcome after encephalo-duro-arterio-synangiosis. Clin Neurol Neurosurg 1997;99 Suppl 2:S151-5.
5. Han DH, Kwon OK, Byun BJ, Choi BY, Choi CW, Choi JU, et al. A co-operative study: Clinical characteristics of 334 Korean patients with Moyamoya disease treated at neurosurgical institutes (1976-1994). The Korean society for cerebrovascular disease. Acta Neurochir (Wien) 2000;142:1263-73.
6. Mineharu Y, Liu W, Inoue K, Matsuura N, Inoue S, Takenaka K, et al. Autosomal dominant Moyamoya disease maps to chromosome 17q25.3. Neurology 2008;70:2357-63.
7. Wang R, Xu Y, Lv R, Chen J. Systemic lupus erythematosus associated with Moyamoya syndrome: A case report and literature review. Lupus 2013;22:629-33.
8. Kendall B. Cerebral angiography in vasculitis affecting the nervous system. Eur Neurol 1984;23:400-6.
9. Sasaki T, Nogawa S, Amano T. Co-morbidity of Moyamoya disease with Graves’ disease. Report of three cases and a review of the literature. Intern Med 2006;45:649-53.
10. Carhuapoma JR, D’Olaberriague L, Levine SR. Moyamoya syndrome associated with Sneddon’s syndrome and antiphospholipid protein antibodies. J Stroke Cerebrovasc Dis 1999;8:51-6.
11. Fukui M, Kono S, Sueishi K, Ikezaki K. Moyamoya disease. Neuropathology 2000;20 Suppl:S61-4.
12. Alexandrov AV, Sharma VK, Lao AY, Tsivgoulis G, Malkoff MD, Alexandrov AW, et al. Reversed Robin Hood syndrome in acute ischemic stroke patients. Stroke 2007;38:3045-8.
13. Ahmad A, Paliwal P, Wakerley BR, Teoh HL, Sharma VK. Vascular contribution to hyperglycaemia-induced hemichorea. Diab Vase Dis Res 2013;10:378-9.
14. Akamatsu Y, Fujimura M, Sakata H, Endo H, Itabashi R, Tominaga T, et al. A case of akin Moyamoya disease associated with type-I diabetes mellitus managed by extracranial-intracranial bypass. No Shinkei Geka 2015;43:227-33.
15. Hughes JW, Wyckoff JA, Hollander AS, Derdeyn CP, McGill JB. Moyamoya syndrome causing stroke in young women with type I diabetes. J Diabetes Complications 2016;30:1640-2.
16. Chen JB, Liu Y, Zhou LX, Sun H, He M, You C, et al. Prevalence of autoimmune disease in moyamoya disease patients in Western Chinese population. J Neurol Sci 2015;351:184-6.
17. Bower RS, Mallory GW, Nwojo M, Kudva YC, Flemming KD, Meyer FB, et al. Moyamoya disease in a primarily white,
Midwestern US population: Increased prevalence of autoimmune disease. Stroke 2013;44:1997-9.
18. Wang CY, Grupke SL, Roberts J, Lee J, Fraser JF. Factors associated with Moyamoya syndrome in a Kentucky regional population. J Stroke Cerebrovasc Dis 2018;27:793-800.
19. Ye L. The Epidemiology of Autoimmune Disease. Foreign Medical Sciences (Section of Dermatology and Venereology); 1982.
20. Bower RS, Mallory GW, Nwojo M, Meyer FB, Kudva YC. Diabetes mellitus and the Moyamoya syndrome. Ann Intern Med 2012;157:387-8.
21. Kushima K, Satoh Y, Ban Y, Taniyama M, Ito K, Sugita K, et al. Graves’ thyrotoxicosis and Moyamoya disease. Can J Neurol Sci 1991;18:140-2.
22. Bonduel M, Hepner M, Sciuccati G, Torres AF, Tenembaum S. Prothrombotic disorders in children with Moyamoya syndrome. Stroke 2001;32:1786-92.
23. Provost TT, Moses H, Morris EL, Altman J, Harley JB, Alexander E, et al. Cerebral vasculopathy associated with collateralization resembling Moya Moya phenomenon and with anti-ro(SS-A) and anti-la(SS-B) antibodies. Arthritis Rheum 1991;34:1052-5.